Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Cyclerion Therapeutics

Rank#10829

Market Cap15.73M

CountryUnited States

Summary

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

History

Cyclerion Therapeutics was founded in 2017 as a spin-off of Ironwood Pharmaceuticals and Flagship Pioneering. The company is focused on discovering, developing and commercializing novel small molecule drugs for diseases involving oxidative stress.

Mission

Our mission is to discover and develop treatments for diseases involving oxidative stress by leveraging our integrated scientific and clinical development capabilities.

Vision

Our vision is to become the premier developer of drugs for diseases involving oxidative stress, with a pipeline of innovative medicines that make a meaningful difference in patients’ lives.

References

https://in.investing.com/equities/cyclerion-therapeutics

https://finance.yahoo.com/quote/CYCN/profile?p=CYCN

https://www.crunchbase.com/organization/cyclerion-therapeutics-inc

https://companiesmarketcap.com/

https://www.cyclerion.com

Leadership team

Dr. Peter M. Hecht Ph.D. (CEO & Director)

Ms. Cheryl Gault (Chief Operating Officer)

Ms. Anjeza Gjino (CFO & Corp. Sec.)

Products / Services

Biotechnology, Pharmaceutical

Address

Cambridge, Massachusetts, United States

Established

2019-01-01

Company Registration

SEC CIK number: 0001755237

Traded as

CYCN

Website

https://www.cyclerion.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Cyclerion Therapeutics

Rank#10829

Market Cap15.73M

CountryUnited States

Summary

History

Mission

Our mission is to discover and develop treatments for diseases involving oxidative stress by leveraging our integrated scientific and clinical development capabilities.

Vision

Our vision is to become the premier developer of drugs for diseases involving oxidative stress, with a pipeline of innovative medicines that make a meaningful difference in patients’ lives.

References

https://in.investing.com/equities/cyclerion-therapeutics

https://finance.yahoo.com/quote/CYCN/profile?p=CYCN

https://www.crunchbase.com/organization/cyclerion-therapeutics-inc

https://companiesmarketcap.com/

https://www.cyclerion.com

Leadership team

Dr. Peter M. Hecht Ph.D. (CEO & Director)

Ms. Cheryl Gault (Chief Operating Officer)

Ms. Anjeza Gjino (CFO & Corp. Sec.)

Products / Services

Biotechnology, Pharmaceutical